Cargando…

Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses

Although antibodies that effectively neutralize a broad set of influenza viruses exist in the human antibody repertoire, they are rare. We used a single-cell screening technology to identify rare monoclonal antibodies (MAbs) that recognized a broad set of influenza B viruses (IBV). The screen yielde...

Descripción completa

Detalles Bibliográficos
Autores principales: Vigil, Adam, Estélles, Angeles, Kauvar, Lawrence M., Johnson, Scott K., Tripp, Ralph A., Wittekind, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923107/
https://www.ncbi.nlm.nih.gov/pubmed/29507069
http://dx.doi.org/10.1128/AAC.02269-17
_version_ 1783318276993974272
author Vigil, Adam
Estélles, Angeles
Kauvar, Lawrence M.
Johnson, Scott K.
Tripp, Ralph A.
Wittekind, Michael
author_facet Vigil, Adam
Estélles, Angeles
Kauvar, Lawrence M.
Johnson, Scott K.
Tripp, Ralph A.
Wittekind, Michael
author_sort Vigil, Adam
collection PubMed
description Although antibodies that effectively neutralize a broad set of influenza viruses exist in the human antibody repertoire, they are rare. We used a single-cell screening technology to identify rare monoclonal antibodies (MAbs) that recognized a broad set of influenza B viruses (IBV). The screen yielded 23 MAbs with diverse germ line origins that recognized hemagglutinins (HAs) derived from influenza strains of both the Yamagata and Victoria lineages of IBV. Of the 23 MAbs, 3 exhibited low expression in a transient-transfection system, 4 were neutralizers that bound to the HA head region, 11 were stalk-binding nonneutralizers, and 5 were stalk-binding neutralizers, with 4 of these 5 having unique antibody sequences. Of these four unique stalk-binding neutralizing MAbs, all were broadly reactive and neutralizing against a panel of multiple strains spanning both IBV lineages as well as highly effective in treating lethal IBV infections in mice at both 24 and 72 h postinfection. The MAbs in this group were thermostable and bound different epitopes in the highly conserved HA stalk region. These characteristics suggest that these MAbs are suitable for consideration as candidates for clinical studies to address their effectiveness in the treatment of IBV-infected patients.
format Online
Article
Text
id pubmed-5923107
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-59231072018-05-11 Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses Vigil, Adam Estélles, Angeles Kauvar, Lawrence M. Johnson, Scott K. Tripp, Ralph A. Wittekind, Michael Antimicrob Agents Chemother Antiviral Agents Although antibodies that effectively neutralize a broad set of influenza viruses exist in the human antibody repertoire, they are rare. We used a single-cell screening technology to identify rare monoclonal antibodies (MAbs) that recognized a broad set of influenza B viruses (IBV). The screen yielded 23 MAbs with diverse germ line origins that recognized hemagglutinins (HAs) derived from influenza strains of both the Yamagata and Victoria lineages of IBV. Of the 23 MAbs, 3 exhibited low expression in a transient-transfection system, 4 were neutralizers that bound to the HA head region, 11 were stalk-binding nonneutralizers, and 5 were stalk-binding neutralizers, with 4 of these 5 having unique antibody sequences. Of these four unique stalk-binding neutralizing MAbs, all were broadly reactive and neutralizing against a panel of multiple strains spanning both IBV lineages as well as highly effective in treating lethal IBV infections in mice at both 24 and 72 h postinfection. The MAbs in this group were thermostable and bound different epitopes in the highly conserved HA stalk region. These characteristics suggest that these MAbs are suitable for consideration as candidates for clinical studies to address their effectiveness in the treatment of IBV-infected patients. American Society for Microbiology 2018-04-26 /pmc/articles/PMC5923107/ /pubmed/29507069 http://dx.doi.org/10.1128/AAC.02269-17 Text en Copyright © 2018 Vigil et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Antiviral Agents
Vigil, Adam
Estélles, Angeles
Kauvar, Lawrence M.
Johnson, Scott K.
Tripp, Ralph A.
Wittekind, Michael
Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
title Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
title_full Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
title_fullStr Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
title_full_unstemmed Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
title_short Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
title_sort native human monoclonal antibodies with potent cross-lineage neutralization of influenza b viruses
topic Antiviral Agents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923107/
https://www.ncbi.nlm.nih.gov/pubmed/29507069
http://dx.doi.org/10.1128/AAC.02269-17
work_keys_str_mv AT vigiladam nativehumanmonoclonalantibodieswithpotentcrosslineageneutralizationofinfluenzabviruses
AT estellesangeles nativehumanmonoclonalantibodieswithpotentcrosslineageneutralizationofinfluenzabviruses
AT kauvarlawrencem nativehumanmonoclonalantibodieswithpotentcrosslineageneutralizationofinfluenzabviruses
AT johnsonscottk nativehumanmonoclonalantibodieswithpotentcrosslineageneutralizationofinfluenzabviruses
AT trippralpha nativehumanmonoclonalantibodieswithpotentcrosslineageneutralizationofinfluenzabviruses
AT wittekindmichael nativehumanmonoclonalantibodieswithpotentcrosslineageneutralizationofinfluenzabviruses